Search Results for: stem cells for ms

Scientists try not to lose it with their labs shut by the pandemic

light-at-the-end-of-the-tunnel

How can we scientists find ways to keep doing our research during the COVID19 pandemic even if it has nothing to do with the coronavirus? Also, how should those of us involved in science communication talk about the outbreak? At a more basic level, how can scientists try not to go bonkers during this dark […]

Scientists try not to lose it with their labs shut by the pandemic Read More »

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more

cell therapy for COVID

  It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »

Cell therapy trials for COVID-19 accelerate & some early reports

MultiStem-Athersys-cell-therapy-COVID-19

Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a

Cell therapy trials for COVID-19 accelerate & some early reports Read More »

Interview with Sean Morrison on cellular therapies for COVID-19

Sean-Morrison

To get at addressing what’s the real deal on the idea of cellular therapies for COVID-19, I did a short email Q&A interview with Dr. Sean Morrison. Sean is Chair of the Public Policy Committee at ISSCR and Director of Children’s Research Institute at UT Southwestern. He was also President of ISSCR in 2015-2016, and

Interview with Sean Morrison on cellular therapies for COVID-19 Read More »

As clinics buzz about coronavirus, COVID19 patient given non-FDA-approved exosomes?

Kimera-Labs-exosomes-COVID-19-novel-coronavirus-disease

When the number of stem cell clinical studies and trials listed for COVID-19 first started spiraling upward it seemed likely that stem cell clinics and other firms in that arena would get interested. I thought that we’d see the unproven regenerative medicine coronavirus bandwagon quickly grow. Unfortunately, there are reasons to be increasingly concerned here. For instance,

As clinics buzz about coronavirus, COVID19 patient given non-FDA-approved exosomes? Read More »

‘Captain Kirk’ regenerative clinic supplier Invitrx gets long FDA warning letter

Habib-Torfi

Should we call it stem cell synchronicity for stem cell supplier firm Invitrx? What was it about March 16? Sometimes strange things happen in the stem cell world such as last week on March 16 I wrote that the FDA needs to do more about unproven exosomes, and then on the same day a new FDA warning

‘Captain Kirk’ regenerative clinic supplier Invitrx gets long FDA warning letter Read More »

Liveyon is back (again) with unproven exosome product

Liveyon

Remember our old friends Liveyon? Their leader John Kosolcharoen? Liveyon’s continuing metamorphosis This biologics supply firm has gone through several stages of corporate metamorphosis as a supplier of biologics including at first a purported living umbilical cord stem cell product. That stem cell thrust ultimately landed a dozen or more people in the hospital as

Liveyon is back (again) with unproven exosome product Read More »

Regenerative medicine recommended reads including $191 million to researcher

Mark-Pennesi-CRISPR-regenerative-medicine-eye

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as

Regenerative medicine recommended reads including $191 million to researcher Read More »

Heads up on Hui Yang, another potential aspiring CRISPR baby researcher

-Yui-Hang

Making a CRISPR baby is a controversial idea to even propose now for many reasons, yet even after He Jiankui’s train wreck some people have seemed eager to try it including apparently a scientist whose name perhaps many readers here are not so familiar with in this context: Professor Hui Yang. ‘CRISPR baby guys’ Is

Heads up on Hui Yang, another potential aspiring CRISPR baby researcher Read More »